Agora-X Gains Backer

The new ECN, founded by commodity risk management firm FCStone Group and expected to launch mid-year, will initially provide trading of OTC option "look-alikes" in specific energy and agricultural commodities, as well as all commodity swaps in conjunction with those trades (DWT, Jan. 14).

Nasdaq OMX will acquire a 20 percent equity interest in Agora-X if the full $7.5 million is committed, pending fulfillment of closing conditions and milestones, say officials. The investment will be used to

Only users who have a paid subscription or are part of a corporate subscription are able to print or copy content.

To access these options, along with all other subscription benefits, please contact info@waterstechnology.com or view our subscription options here: http://subscriptions.waterstechnology.com/subscribe

You are currently unable to copy this content. Please contact info@waterstechnology.com to find out more.

Sorry, our subscription options are not loading right now

Please try again later. Get in touch with our customer services team if this issue persists.

New to Waterstechnology? View our subscription options

Register for free

Access two articles, our IMD and Waters Wraps, plus a member newsletter. Find out more.

All fields are mandatory unless otherwise highlighted.

This address will be used to create your account

Banks seemingly build more than buy, but why?

Waters Wrap: A new report states that banks are increasingly enticed by the idea of building systems in-house, versus being locked into a long-term vendor contract. Anthony explores the reason for this shift.

Pushing the boundaries of TCA

S&P Global Market Intelligence finished runner-up in the perennially competitive TCA system provider category of the Waters Rankings 2024. Michael Richter, global head of trading analytics, discusses the TCA challenges facing the firm’s buy- and sell…

Most read articles loading...

You need to sign in to use this feature. If you don’t have a WatersTechnology account, please register for a trial.

Sign in
You are currently on corporate access.

To use this feature you will need an individual account. If you have one already please sign in.

Sign in.

Alternatively you can request an individual account here